Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1

Status

Recruiting 20Active not recruiting 11Withdrawn 6Not yet recruiting 4Terminated 3Completed 3Available 2Suspended 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 2Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hemangiosarcoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × balstilimab × Clear all
NCT05363709 2026-05-12

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Oropharyngeal Neoplasms

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

City of Hope Medical Center

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05033132 2024-03-28

A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Agenus Inc.

Phase 2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT05561491 2023-06-22

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Targovax ASA

Phase 2 Withdrawn
Dermatologic

Melanoma, Neoplasm Metastasis

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡